The independent medical news service
Kidney cancer
27-04-2022 | Oncology | News | Article
Neurologic AE risk lower with ICIs vs chemotherapy
The risk for neurologic adverse events is significantly lower with immune checkpoint inhibitors than with other cancer treatments, particularly chemotherapy, suggest results of a systematic review and meta-analysis.
18-01-2022 | Oncology | News | Article
Reassurance on radiotherapy use prior to ICI initiation
Treatment with immune checkpoint inhibitors within 90 days of radiotherapy does not lead to a “meaningful increase” in rates of serious adverse events, say researchers who conducted a pooled analysis of US FDA registry data.
21-09-2021 | Oncology | News | Article
Drug-free interval feasible in metastatic RCC
Incorporating a drug-free interval into first-line treatment for metastatic clear cell renal cell carcinoma may not be detrimental to patient survival or quality of life, suggest STAR trial data presented at the ESMO Congress 2021.